Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease
China40 participantsStarted 2025-01-26
Plain-language summary
The goal of this clinical trial is to learn if ultrasound-guided stellate ganglion block (SGB), added to standard drug treatment, can improve thinking and memory in people with Alzheimer's disease. It will also learn about the safety of SGB.
The main questions this study aims to answer are:
Do people who receive SGB plus standard drug treatment have better global cognition, measured by the Mini-Mental State Examination (MMSE), 1 month after finishing the treatment course compared with people who receive standard drug treatment alone? How do anxiety, depression, quality of life, and ability to live independently change over 1 month, 3 months, and 6 months after treatment? What medical problems, if any, occur during or after SGB?
Researchers will compare two groups:
SGB plus standard drug treatment Standard drug treatment alone
Participants will:
Be randomly assigned to one of the two groups Receive the assigned treatment Complete study visits and assessments at baseline and at 1 month, 3 months, and 6 months after finishing the treatment course
Who can participate
Age range55 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 55 to 85 years.
✓. Diagnosis of Alzheimer's disease (AD) based on the 2011 NIA-AA criteria.
✓. Mild to moderate cognitive impairment assessed by the Mini-Mental State Examination (MMSE).
✓. Ability to understand study procedures and provide written informed consent by the participant or a legally authorized representative.
✓. Ability to complete scheduled follow-up assessments.
Exclusion criteria
✕. Known allergy to lidocaine, coagulation disorders, or other contraindications to stellate ganglion block (SGB).
✕. Severe cardiac, hepatic, or renal disease that could compromise safety.
✕. Cranial surgery or major head trauma within the past 6 months.
✕. Participation in other interventional trials that could affect study outcomes.
✕
What they're measuring
1
Mini-Mental State Examination (MMSE) Total Score
Timeframe: Baseline; Day 20 (end of treatment course); and 1, 3, and 6 months after completion of the treatment course.